DaVita Inc. (NYSE:DVA) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC trimmed its holdings in DaVita Inc. (NYSE:DVA) by 33.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,813 shares of the company’s stock after selling 2,419 shares during the period. Guggenheim Capital LLC’s holdings in DaVita were worth $720,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in DaVita in the fourth quarter valued at approximately $316,000. Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita during the 4th quarter worth $55,000. Promethos Capital LLC raised its position in shares of DaVita by 3.5% in the 4th quarter. Promethos Capital LLC now owns 29,396 shares of the company’s stock worth $4,396,000 after buying an additional 1,000 shares during the period. CreativeOne Wealth LLC boosted its holdings in DaVita by 12.5% in the fourth quarter. CreativeOne Wealth LLC now owns 3,729 shares of the company’s stock valued at $558,000 after acquiring an additional 415 shares during the last quarter. Finally, Mariner LLC grew its position in DaVita by 3.8% during the fourth quarter. Mariner LLC now owns 6,438 shares of the company’s stock valued at $963,000 after acquiring an additional 233 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on DVA. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Performance

Shares of DVA stock opened at $139.64 on Friday. The company’s fifty day moving average price is $146.81 and its two-hundred day moving average price is $155.40. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The firm has a market capitalization of $11.17 billion, a P/E ratio of 13.00, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12 month low of $130.96 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.